Clinical trial

Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers

NCT02725489

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

BIOLOGICAL · Unmapped registry intervention Vigil Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Durvalumab Normalized identity: durvalumabView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2016-06-03

PhasePHASE2

Conditions

Breast Cancerverified · MONDO: breast cancer

Ovarian Cancerverified · MONDO: ovarian cancer

Fallopian Tube Cancerverified · MONDO: fallopian tube cancer

Primary Peritoneal Carcinomaverified · MONDO: primary peritoneal carcinoma

Uterine Cancerverified · MONDO: uterine cancer

Cervical Cancerverified · MONDO: cervical cancer

Endometrial Cancerverified · MONDO: endometrial cancer

Interventions

VigilBIOLOGICAL

DurvalumabDRUG · verified · RxNorm: durvalumab

Sponsors & collaborators

Mary Crowley Medical Research Centerlead sponsor

Gradalis, Inc.collaborator

AstraZenecacollaborator

Mapped research locations

DallasTexas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02725489 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.